
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated …